Aytu BioPharma announced receipt of U.S. Food & Drug Administration approval of the Cotempla XR-ODT Prior Approval Supplement. This approval enables the transfer of manufacturing of Cotempla to the Company’s third-party manufacturer and follows a similar achievement for Adzenys XR- ODT which received PAS approval in April 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AYTU:
